Biosimilars
Low switch-back for patients treated with Avsola for IBD
A study has reported low switch-back rates for patients with inflammatory bowel disease (IBD) switched from the reference infliximab product to Amgen’s biosimilar Avsola (infliximab-axxq), ABP 710 [1].
EMA recommends approval of eculizumab biosimilar Epysqli
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 31 March 2023 that it had adopted a positive opinion for Epysqli.
Joint statement on biosimilars in immune-mediated diseases in Spain
A study conducted and published by Monte-Boquet E et al. aimed to improve knowledge and use of biosimilar medicines in immune-mediated diseases, and to produce a unified framework for the use of biosimilars [1].
High mannose glycans in biosimilars and their pharmacokinetic impact
A study conducted by Welch J et al. assessed the measurement, evaluation and potential for high mannose glycans to impact the pharmacokinetic (PK) profile of biosimilar monoclonal antibodies (mAbs), based on data submitted in 21 applications reviewed and approved by the US Food and Drug Administration (FDA). They also analysed reproducibility data of the glycan values for a subset of programmes within a reference product class. This reproducibility assessment enabled a broader cross-programme comparison of whether observed differences in high mannose between a proposed biosimilar and its reference product translate into PK differences.
New indication for Cosentyx (secukinumab) biological: hidradenitis suppurativa
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use adopted a positive opinion on 26 April 2023 recommending Novartis' Cosentyx (secukinumab) to treat active moderate to severe hidradenitis suppurativa (HS) in adults.
An update on the joint EMA-HMA statement on interchangeability of biosimilar
On 21 April 2023, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) issued an updated joint statement on the interchangeability of biosimilars approved in the EU.
Biosimilars in Southern European Hospital Markets: barriers and determinants of uptake
A recent publication by Barcina Lacosta et al. reflected on the need to understand market dynamics generated following biosimilars availability in Southern Europe, emphasizing that the competitive potential of biosimilars can be further deployed [1]. Considering the country-, setting-, and product-specific nature of biosimilar uptake patterns [2-5], the authors focused the analysis on hospital tumour necrosis factor alpha (TNF-α) inhibitor markets in Italy, Portugal and Spain [1].
Advances for STADA-Xbrane’s Ximluci in Europe, the UK and the US
The STADA and Xbrane co-developed Ximluci, ranibizumab biosimilar is to launch in Europe and will now also be available on the UK’s National Health Service (NHS). In addition, the partners have submitted their Biologics License Application (BLA) to the US Food and Drug Administration (FDA).
Biosimilars switching policies for Canada’s Newfoundland and Labrador, and Yukon
The Canadian provinces of Newfoundland and Labrador, and Yukon, become the 9th and 10th Canadian provinces to announce that they are adopting biosimilars switching policies.
Advancing biosimilar drug development with pharmacodynamic biomarkers
US Food and Drug Administration (FDA) researchers are studying the use of pharmacodynamic (PD) biomarkers to demonstrate biosimilarity. These studies could make the process of developing biosimilars more efficient and faster.
